DalCor Pharmaceuticals announces Dal-GenE-2 confirmatory trial and closing of Series D financing round
DalCor Pharmaceuticals today announced the closing of the company’s Series D financing round of $80m USD to conduct the Dal-GenE-2 confirmatory trial in North America under a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA).
dal-GenE Phase 3 Cardiovascular Precision Medicine Outcomes Trial Results Published in European Heart Journal
Trial was negatively impacted by the COVID-19 pandemic and did not meet the primary endpoint. However, the results validate the interaction between dalcetrapib treatment and AA genotype at variant rs1967309 in the ADCY9 gene.
DalCor Pharmaceuticals today announced that the independent dal-GenE Data and Safety Monitoring Board (DSMB) recommends the dal-GenE pivotal outcomes trial should continue as planned with no modifications.
DalCor Pharmaceuticals today announced the appointment of Dr. David G. Kallend as Chief Scientific Officer effective July 1, 2020.
DalCor Pharmaceuticals today announced the appointment of Diane E. Sullivan as Chief Commercial Officer effective June 1, 2020. Ms. Sullivan joins DalCor from The Medicines Company where she held the position of Chief Commercial Officer and has extensive leadership experience in both life sciences and technology at U.S. and U.K. based multi-national corporations.
DalCor Pharmaceuticals today announced that following the results of the interim futility analysis of the dalcetrapib dal-GenE Phase 3 trial, DalCor will continue the dal-GenE trial as recommended by the independent Data and Safety Monitoring Board (DSMB).
DalCor Pharmaceuticals today announced the appointment of Paul R. Fonteyne to Chairman of the Board effective February 27, 2019.
DalCor Announces Completion of Patient Enrollment in dal-GenE, the First Phase 3 Precision Medicine Cardiovascular Outcomes Trial in Coronary Heart Disease
DalCor today announced the completion of patient enrollment in the dal-GenE study, the first Phase 3 precision medicine cardiovascular outcomes trial in coronary heart disease.
DalCor today announced the appointment of Peter Schuepbach as Vice President of Technical Operations.
DalCor Pharmaceuticals today announced the appointment of Dr. Fouzia Laghrissi-Thode as Chief Executive Officer, effective April 3, 2018. Dr. Laghrissi-Thode is currently on the Board of Directors for DalCor.